# A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

> **NCT00883779** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 451 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** Platinum chemotherapy (cisplatin or carboplatin)
- **DRUG:** erlotinib [Tarceva]
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00883779
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 451 (ACTUAL)
- **Last updated:** 2015-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00883779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00883779, "A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00883779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*